Earlier today, the US Food and Drug Administration (FDA) approved relugolix, (Orgovyx, from Myovant Sciences), the first, oral luteinizing hormone releasing hormone (LHRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antagonist, GnRH, LHRH, Myovant, Orgovyx, relugolix | 6 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 